modelA07FA03
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | EscherichiaColi | |
| ATC code: | A07FA03 | route: | oral |
| compartments: | 0 | |
| dosage: | 250 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Escherichia coli (E. coli) Nissle 1917 is a probiotic preparation used in some countries for the treatment and prevention of gastrointestinal disorders such as ulcerative colitis, irritable bowel syndrome, and infectious diarrhea. This drug is composed of live, non-pathogenic E. coli bacteria and is classified under intestinal anti-inflammatory/anti-infective microorganisms. It is not universally approved and is not used in the United States, but is utilized in a number of European and other countries for gastrointestinal disease management.
Pharmacokinetics
No published pharmacokinetic studies exist as E. coli Nissle 1917 is a live probiotic microorganism and not absorbed systemically. Thus, typical pharmacokinetic parameters such as absorption, distribution, metabolism, and elimination are not applicable.
References
Kim, P, et al., & Garofolo, PM (2024). Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. The Lancet. Infectious diseases 24(12) 1319–1332. DOI:10.1016/S1473-3099(24)00424-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39134085
Keij, FM, et al., & Flint, RB (2023). Oral and Intravenous Amoxicillin Dosing Recommendations in Neonates: A Pooled Population Pharmacokinetic Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 77(11) 1595–1603. DOI:10.1093/cid/ciad432 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37757471
Hirt, D, et al., & Benaboud, S (2021). Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. European journal of clinical pharmacology 77(11) 1687–1695. DOI:10.1007/s00228-021-03174-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34160669
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)